NextCure Inc Total Liabilities
NextCure Inc total liabilities. Based on the latest financial reports, NextCure Inc (NXTC) has total liabilities worth $10.47 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check NXTC financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of NextCure Inc (2017–2025)
Total liabilities of NextCure Inc from 2017 to 2025. This chart illustrates how NextCure Inc's total liabilities have evolved over time, based on quarterly financial data.
NextCure Inc Competitors by Total Liabilities
The table below lists competitors of NextCure Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bantas Bandirma Ambalaj Sanayi ve Ticaret AS
IS:BNTAS
|
Turkey | TL21.32 Million |
|
Barunson Co. Ltd
KQ:018700
|
Korea | ₩13.18 Billion |
|
AMICCOM Electronics
TWO:5272
|
Taiwan | NT$179.63 Million |
|
Abko Co. Ltd
KQ:129890
|
Korea | ₩46.18 Billion |
|
Przedsiebiorstwo Produkcyjno Handlowe Kompap SA
WAR:KMP
|
Poland | zł35.36 Million |
|
Trajan Group Holdings Ltd
AU:TRJ
|
Australia | AU$89.27 Million |
|
IL&FS Investment Managers Limited
NSE:IVC
|
India | Rs324.05 Million |
|
Terramin Australia Ltd
AU:TZN
|
Australia | AU$60.11 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down NextCure Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see NXTC current and non-current assets.
Liquidity & Leverage Metrics
NextCure Inc Total Liabilities Ratios Explained
NextCure Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.47 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.86 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NextCure Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NextCure Inc (2017–2025)
The table below shows the annual total liabilities of NextCure Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $15.24 Million | -0.96% |
| 2024-12-31 | $15.39 Million | +13.01% |
| 2023-12-31 | $13.62 Million | -18.12% |
| 2022-12-31 | $16.63 Million | +84.79% |
| 2021-12-31 | $9.00 Million | -30.36% |
| 2020-12-31 | $12.92 Million | -62.74% |
| 2019-12-31 | $34.68 Million | -82.17% |
| 2018-12-31 | $194.57 Million | +343.43% |
| 2017-12-31 | $43.88 Million | -- |
About NextCure Inc
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leuke… Read more